Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
(RTTNews) - The U.S. Food and Drug Administration approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult...
The Hepzato Kit is a direct-to-liver therapy for patients with uveal melanoma with hepatic metastases.
The FDA approved Delcath Systems Inc's (NASDAQ: DCTH) HEPZATO KIT (melphalan/Hepatic Delivery System).
- Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation ...